178 related articles for article (PubMed ID: 22691048)
1. Diagnostic utility of cytokeratin 17 immunostaining in morpheaform basal cell carcinoma and for facilitating the detection of tumor cells at the surgical margins.
Anderson-Dockter H; Clark T; Iwamoto S; Lu M; Fiore D; Falanga JK; Falanga V
Dermatol Surg; 2012 Aug; 38(8):1357-66. PubMed ID: 22691048
[TBL] [Abstract][Full Text] [Related]
2. The immunohistochemical differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and morpheaform basal cell carcinoma using BerEP4 and stem cell markers.
Sellheyer K; Nelson P; Kutzner H; Patel RM
J Cutan Pathol; 2013 Apr; 40(4):363-70. PubMed ID: 23398472
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of cytokeratin 15, TDAG51, cytokeratin 20 and androgen receptor in sclerosing adnexal neoplasms and variants of basal cell carcinoma.
Evangelista MT; North JP
J Cutan Pathol; 2015 Nov; 42(11):824-31. PubMed ID: 26016446
[TBL] [Abstract][Full Text] [Related]
4. Commentary: diagnostic utility of cytokeratin 17 immunostaining in morpheaform basal cell carcinoma and for facilitating the detection of tumor cells at the surgical margins.
Baum CL
Dermatol Surg; 2012 Aug; 38(8):1367-8. PubMed ID: 22861061
[No Abstract] [Full Text] [Related]
5. Morpheaform Basal Cell Carcinomas With Areas of Predominantly Single-Cell Pattern of Infiltration: Diagnostic Utility of p63 and Cytokeratin.
East E; Fullen DR; Arps D; Patel RM; Palanisamy N; Carskadon S; Harms PW
Am J Dermatopathol; 2016 Oct; 38(10):744-50. PubMed ID: 27043336
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast-activation protein: a single marker that confidently differentiates morpheaform/infiltrative basal cell carcinoma from desmoplastic trichoepithelioma.
Abbas O; Richards JE; Mahalingam M
Mod Pathol; 2010 Nov; 23(11):1535-43. PubMed ID: 20711172
[TBL] [Abstract][Full Text] [Related]
7. Use of Cytokeratin 17 in the Differentiation Between Desmoplastic Trichilemmoma and Cutaneous Basal Cell Carcinoma.
Chaudet KM; Stagner AM; Nazarian RM
Am J Dermatopathol; 2022 Dec; 44(12):886-890. PubMed ID: 36197047
[TBL] [Abstract][Full Text] [Related]
8. Desmoplastic trichoepithelioma, infiltrative/morpheaform BCC, and microcystic adnexal carcinoma: differentiation by immunohistochemistry and determining the need for Mohs micrographic surgery.
Merritt BG; Snow SN; Longley BJ
Cutis; 2010 May; 85(5):254-8. PubMed ID: 20540416
[TBL] [Abstract][Full Text] [Related]
9. Elastic fiber staining and cytokeratin 15 expression pattern in trichoepithelioma and basal cell carcinoma.
Choi CW; Park HS; Kim YK; Lee SH; Cho KH
J Dermatol; 2008 Aug; 35(8):499-502. PubMed ID: 18789069
[TBL] [Abstract][Full Text] [Related]
10. Differentiation between basal cell carcinoma and trichoepithelioma by immunohistochemical staining of the androgen receptor: an overview.
Arits AH; Van Marion AM; Lohman BG; Thissen MR; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
Eur J Dermatol; 2011; 21(6):870-3. PubMed ID: 21865121
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of CD10 and Bcl2 expression in distinguishing cutaneous basal cell carcinoma from squamous cell carcinoma and seborrheic keratosis.
Gaballah MA; Ahmed RA
Pathol Res Pract; 2015 Dec; 211(12):931-8. PubMed ID: 26573127
[TBL] [Abstract][Full Text] [Related]
12. Expression of p16 Protein in Cutaneous Basal Cell Carcinoma: Still far from Being Clearly Understood.
Bartoš V
Acta Dermatovenerol Croat; 2020 Jul; 28(1):43-44. PubMed ID: 32650852
[TBL] [Abstract][Full Text] [Related]
13. Cytokeratin 17 is highly sensitive in discriminating cutaneous lymphadenoma (a distinct trichoblastoma variant) from basal cell carcinoma.
Goyal A; Solus JF; Chan MP; Doyle LA; Schaffer A; Thakuria M; Horn TD; Duncan LM; Nazarian RM
J Cutan Pathol; 2016 May; 43(5):422-9. PubMed ID: 26968559
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic accuracy of immunohistochemical markers in differentiation between basal cell carcinoma and trichoepithelioma in small biopsy specimens.
Mostafa NA; Assaf M; Elhakim S; Abdel-Halim MRE; El-Nabarawy E; Gharib K
J Cutan Pathol; 2018 Nov; 45(11):807-816. PubMed ID: 29917261
[TBL] [Abstract][Full Text] [Related]
15. Ln-γ 2 chain of laminin-332 is a useful marker in differentiating between benign and malignant sclerosing adnexal neoplasms.
Koga K; Anan T; Fukumoto T; Fujimoto M; Nabeshima K
Histopathology; 2020 Jan; 76(2):318-324. PubMed ID: 31429981
[TBL] [Abstract][Full Text] [Related]
16. Microcystic adnexal carcinoma: an immunohistochemical reappraisal.
Hoang MP; Dresser KA; Kapur P; High WA; Mahalingam M
Mod Pathol; 2008 Feb; 21(2):178-85. PubMed ID: 18065959
[TBL] [Abstract][Full Text] [Related]
17. Does Immunohistochemistry Add to Morphology in Differentiating Trichoepithelioma, Desmoplastic Trichoepithelioma, Morpheaform Basal Cell Carcinoma, and Microcystic Adnexal Carcinoma?
Mohanty SK; Sardana R; McFall M; Pradhan D; Usmani A; Jha S; Mishra SK; Sampat NY; Lobo A; Wu JM; Balzer BL; Frishberg DP
Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):273-277. PubMed ID: 35384877
[TBL] [Abstract][Full Text] [Related]
18. Desmoplastic Trichoepithelioma: An Uncommon but Diagnostically Problematic Benign Adnexal Tumor.
Bartoš V
Acta Dermatovenerol Croat; 2019 Dec; 27(4):282-284. PubMed ID: 31969246
[TBL] [Abstract][Full Text] [Related]
19. Expression of drebrin, an actin binding protein, in basal cell carcinoma, trichoblastoma and trichoepithelioma.
Mizutani Y; Iwamoto I; Kanoh H; Seishima M; Nagata K
Histol Histopathol; 2014 Jun; 29(6):757-66. PubMed ID: 24346822
[TBL] [Abstract][Full Text] [Related]
20. Does the panel of cytokeratin 20 and androgen receptor antibodies differentiate desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma?
Katona TM; Perkins SM; Billings SD
J Cutan Pathol; 2008 Feb; 35(2):174-9. PubMed ID: 18190441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
